IBEX Reports Record Start to Fiscal 2027, Raises Full Year Guidance

IBEX posts record Q1 results, raises full-year revenue and EBITDA guidance.

What the company is saying

IBEX Limited reports a record-breaking start to fiscal 2027, highlighting first quarter revenue of $175.2 million, up 15.9% year-over-year. CEO Bob Dechant attributes the growth to strong performance across HealthTech (+39.9%), Travel, Transportation and Logistics (+16.4%), Technology (+9.8%), and Retail & E-commerce (+8.7%), as well as momentum in digital acquisition and AI Agent solutions, particularly through the Sierra partnership. The company emphasizes its seventh consecutive quarter of double-digit growth and the highest adjusted EBITDA in its history. CFO Taylor Greenwald states that the robust quarter underpins increased confidence in continued double-digit growth and margin expansion, leading to raised full-year guidance for both revenue and adjusted EBITDA. The tone is confident and data-driven, with management crediting higher-margin offshore regions, AI solutions, and operational efficiency for the improved profitability. The announcement also notes ongoing share repurchases and capacity expansion to meet demand.

What the data suggests

The disclosed figures show broad-based financial improvement. Revenue rose to $175.2 million from $151.2 million, a 15.9% increase, with all four main verticals contributing to growth. Net income increased to $14.8 million from $12.0 million, and net income margin improved from 8.0% to 8.4%. Adjusted net income reached $16.4 million, up from $13.1 million, with the margin expanding to 9.4%. Adjusted EBITDA grew to $25.2 million from $19.5 million, with margin up to 14.4%. Diluted EPS was $0.99, up from $0.82, and adjusted diluted EPS was $1.10, up from $0.90. Cash flow from operations set a first quarter record at $16.3 million, and free cash flow rose to $9.2 million. Net cash increased to $35.0 million from $30.9 million. Capital expenditures were $7.2 million, focused on offshore expansion. The company repurchased 122,806 shares for $4.4 million at an average price of $35.92. Full-year revenue guidance was raised to $720–$735 million (12–14% growth), and adjusted EBITDA guidance to $96–$99 million (17–20% growth), both above previous ranges. The data supports management's claims of momentum and operational leverage, with no evidence of overstatement.

Analysis

The announcement is highly factual and proportionate to the company's actual financial performance. Nearly all key claims are realised and supported by detailed numerical disclosures, including revenue, net income, adjusted EBITDA, margins, cash flow, and capital expenditures. The only forward-looking elements are the raised fiscal year 2027 guidance figures, which are clearly separated from realised results and presented as management's outlook. There is no evidence of narrative inflation or exaggerated claims; the language is confident but grounded in measurable progress. Capital expenditures are moderate and in line with prior periods, with no indication of a large, speculative outlay tied to distant or uncertain returns. The only minor gap is the qualitative attribution of growth to 'digital acquisition and AI Agent solutions' without specific numbers, but this does not materially inflate the overall signal.

Risk flags

• ●Sustaining double-digit growth may become challenging if vertical-specific demand slows or if competitors regain market share, as the current trajectory is partly attributed to strong HealthTech and AI-driven wins.
• ●Geographic concentration in offshore regions such as the Philippines, Jamaica, Pakistan, and Nicaragua exposes IBEX to operational risks from local disruptions, regulatory changes, or geopolitical instability.
• ●The company’s raised capital expenditure guidance to $30 million, at the high end of its prior range, signals increased investment intensity that could pressure free cash flow if revenue growth moderates.
• ●The narrative credits AI Agent solutions and the Sierra partnership for growth, but lacks granular financial breakdowns for these segments, making it harder to independently assess the durability of these drivers.

Bottom line

IBEX Limited delivered a strong Q1, with revenue, net income, and adjusted EBITDA all posting double-digit year-over-year gains and margins expanding across the board. Management’s decision to raise full-year revenue and EBITDA guidance is backed by realised results, robust operating cash flow, and continued share buybacks. The company’s growth is broad-based but especially strong in HealthTech and AI-powered solutions, though detailed financials for new AI initiatives remain limited. Capital expenditures are rising to support offshore expansion, which brings both opportunity and risk. The most important takeaway is that IBEX is executing well on its growth strategy, but investors should monitor the sustainability of vertical growth and the impact of increased investment on future cash generation.

Announcement summary

(NASDAQ:IBEX) IBEX Limited reported financial results for its first fiscal quarter ended September 30, 2026. Revenue for the quarter was $175.2 million, up 15.9% from $151.2 million in the prior year quarter, driven by broad-based growth across four verticals: HealthTech (+39.9%), Travel, Transportation and Logistics (+16.4%), Technology (+9.8%), and Retail & E-commerce (+8.7%), with additional growth in digital acquisition and AI Agent solutions. Net income increased to $14.8 million from $12.0 million, with a net income margin of 8.4% compared to 8.0%. Adjusted net income rose to $16.4 million from $13.1 million, and adjusted net income margin was 9.4% versus 8.7%. Adjusted EBITDA reached $25.2 million, up from $19.5 million, with an adjusted EBITDA margin of 14.4% compared to 12.9%. Diluted earnings per share were $0.99, up from $0.82, and adjusted diluted earnings per share were $1.10, up from $0.90. Capital expenditures for the quarter were $7.2 million, compared to $7.6 million in the prior year, primarily for capacity expansion in high-margin offshore regions. Cash flow from operating activities was $16.3 million, up from $15.7 million, and free cash flow was $9.2 million, up from $8.0 million. Net cash as of September 30, 2026, was $35.0 million, compared to $30.9 million as of June 30, 2026. The company repurchased 122,806 shares for $4.4 million at an average price of $35.92. IBEX raised its fiscal year 2027 guidance, now expecting revenue in the range of $720 to $735 million (12-14% growth), up from previous guidance of $700 to $715 million (9-11% growth). Adjusted EBITDA guidance was raised to $96 to $99 million (17-20% growth), up from $90 to $94 million (9-14% growth). Capital expenditures for the year are expected to be approximately $30 million, at the high end of the previous $25 to $30 million range. The company operates in the United States, Philippines, Jamaica, Pakistan, and Nicaragua. CEO Bob Dechant and CFO Taylor Greenwald commented on the record-breaking quarter and raised outlook. The company will host a conference call and webcast on November 5, 2026, at 4:30 p.m. Eastern Time to discuss results.

Disagree with this article?